SCHEMBL3369249

SCHEMBL3369249

O=C(Nc1ccccc1)c1ccnc(O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.64
HTT P42858 1/20 0.62
KCNK3 O14649 3/20 0.55
HDAC2 Q92769 2/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
HDAC1 Q13547 1/20 0.54
JAK2 O60674 1/20 0.53
TYK2 P29597 1/20 0.53
NPC1 O15118 2/20 0.53
ALDH1A1 P00352 2/20 0.53
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 1/20 0.53
KCNK9 Q9NPC2 2/20 0.51
PTPN1 P18031 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
SIRT1 Q96EB6 2/20 0.50
PLAU P00749 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11134265 0.83 LMNA (0.64) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL14062132 0.82 LMNA (0.62) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL15727556 0.82 LMNA (0.67) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL736261 0.82 LMNA (0.62) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL4599730 0.82 LMNA (0.62) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL15238338 0.82 LMNA (0.62) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL27828455 0.81 CCNC (0.66) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL2868158 0.81 KDM4C (0.64) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL10862923 0.80 LMNA (0.59) LMNAHTTKCNK3HDAC2HDAC8
SCHEMBL1070527 0.79 LMNA (0.56) LMNAHTTKCNK3HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140024583-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-01-23 US disclosed
CN-101460476-B Organic compounds NOVARTIS AG 2013-12-04 CN disclosed
US-8501746-B2 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2013-08-06 US disclosed
WO-2007143597-A9 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-11-11 WO disclosed
EP-2029572-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-11-03 EP disclosed
US-20090156615-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-06-18 US disclosed
CN-101460476-A Organic compounds NOVARTIS AG (CH) 2009-06-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156615-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 LMNA 2176/4885HTT 2592/4885KCNK3 3123/4885
US-20140024583-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 LMNA 2176/4885HTT 2592/4885KCNK3 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.